Qualitative study of patients with dual pathology in treatment with aripiprazole extended-release injectable suspension
| Autor: | L. Fernández Mayo, M. Agujetas Rodríguez, E. Barbero García, D. Baño Rodrigo |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Drug
Pathology medicine.medical_specialty biology business.industry media_common.quotation_subject Craving Extended release injectable suspension biology.organism_classification Dysphoria Psychiatry and Mental health Tolerability Medicine Aripiprazole Cannabis medicine.symptom business Psychopathology medicine.drug media_common |
| Zdroj: | European Psychiatry. 33:S305-S305 |
| ISSN: | 1778-3585 0924-9338 |
| DOI: | 10.1016/j.eurpsy.2016.01.1043 |
| Popis: | IntroductionStudies describe patients with dual pathology as subjects with worse clinical evolution and worse therapeutic response. These subjects have high percentages of worse therapeutic compliance and low adherence to psychopharmacological treatment. The conventional antipsychotics can induce dysphoria and worse craving and drug use. The long duration-injectable antipsychotics could serve as a good therapeutic alternative because they combine efficacy and tolerability.ObjectivesWe analyzed subjects treated with aripiprazole injectable to demonstrate its effectiveness on symptomatology, the reduction of craving and consumption of substances.Materials and methodsWe studied subjects with dual disorders at a Center for Attention to drug addicts treated with aripiprazole extended-release injectable. All of them met criteria for the diagnosis of disorders for cannabis and cocaine use. All of them had been previously treated with oral antipsychotics and/or injectable of long duration. Evolution of craving and consumption were evaluated through clinical interviews and urine analysis.ResultsCannabis was the main substance for all the patients. Three of them also often abused of cocaine. All of them were taking other treatments previously. The main causes of the change were: side effects and/or poor compliance. Only one patient discontinued follow-up. The rest of them showed good therapeutic adherence and better tolerability with aripiprazole injectable. The monthly dose was 400 mg.ConclusionsAripiprazole extended-release injectable is a good choice for dual disorders. A good therapeutic adherence involves not only a psychopathological improvement but also respect to craving and consumption, which makes aripiprazole injectable a suitable therapeutic option.Disclosure of interestThe authors have not supplied their declaration of competing interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|